KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Investments (2016 - 2024)

Historic Long-Term Investments for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q1 2024 value amounting to $11.7 million.

  • Supernus Pharmaceuticals' Long-Term Investments fell 7846.63% to $11.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.7 million, marking a year-over-year decrease of 7846.63%. This contributed to the annual value of $16.6 million for FY2023, which is 8230.28% down from last year.
  • According to the latest figures from Q1 2024, Supernus Pharmaceuticals' Long-Term Investments is $11.7 million, which was down 7846.63% from $16.6 million recorded in Q4 2023.
  • Supernus Pharmaceuticals' Long-Term Investments' 5-year high stood at $534.7 million during Q1 2020, with a 5-year trough of $11.7 million in Q1 2024.
  • Its 5-year average for Long-Term Investments is $215.4 million, with a median of $131.9 million in 2022.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 2420.03% in 2021, then plummeted by 8230.28% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Long-Term Investments (Quarter) stood at $350.4 million in 2020, then plummeted by 65.99% to $119.2 million in 2021, then decreased by 21.21% to $93.9 million in 2022, then crashed by 82.3% to $16.6 million in 2023, then dropped by 29.82% to $11.7 million in 2024.
  • Its Long-Term Investments stands at $11.7 million for Q1 2024, versus $16.6 million for Q4 2023 and $25.1 million for Q3 2023.